A Phase 1 Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma

PURPOSE: CUDC-101 is a small molecule that simultaneously inhibits the epidermal growth factor receptor (EGFR), human growth factor receptor 2 (HER2), and histone deacetylase (HDAC) with preclinical activity in head and neck squamous cell cancer (HNSCC). The primary objective of this investigation i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Galloway, Thomas, Wirth, Lori J., Colevas, Alexander D., Gilbert, Jill, Bauman, Julie E., Saba, Nabil F., Raben, David, Mehra, Ranee, Ma, Anna W., Atoyan, Ruzanna, Wang, Jing, Burtness, Barbara, Jimeno, Antonio
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6607903/
https://ncbi.nlm.nih.gov/pubmed/25573383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2820
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares